Chronic disease program in Iran: Thalassemia control program by Moradi, Ghobad & Ghaderi, Ebrahim
  
http://cdjournal.muk.ac.ir,    7 October 
 
98     Chron Dis J, Vol. 1, No. 2, Autumn 2013 
 
 
Chronic disease program in Iran: Thalassemia control program 
 
Ghobad Moradi1, Ebrahim Ghaderi1 
 
1 Assistant Proffesor, Kurdistan Research Center for Social Determinants of Health (KRCSDH), Kurdistan 
University of Medical Sciences, Sanandaj, Iran 
 
Abstract 
BACKGROUND: β-thalassemias (beta-thalassemia) is the most common genetic disorder; it is an inherited 
globinopathy which is transmitted to people due to a mutation in genes that create globin chain. In Iran, the disease 
gene is more common in the northern and southern regions. It is estimated that more than 60 mutations of the 
disease exist in different geographical areas of Iran. Iran has begun to adopt strategies to control the  
β-thalassemia for two decades; the most important of which is the screening of couples when they want to get 
marry. The present study aimed to review the thalassemia control program in Iran, the history of the disease, and 
the disease control strategies.  
METHODS: This review was conducted according to hand and electronic resources. Books, guidelines and 
document that exist in thalassemia control program were reviewed in the Iranian Ministry of Health, World Health 
Organization resources, PubMed, Google Scholar, SID (scientific information database), Magiran and, Iranmedex. 
RESULTS: Thalassemia program was appropriately structured and has been achieved successes. Reduction the 
numbers of new cases of β-thalassemia were notably. In some areas, thalassemia program has some defects and 
the program faced some cultural barriers. 
CONCLUSION: Due to the improvements in the social and economic situation of the people, it seems necessary to 
focus on prenatal diagnosis (PND) and pre-implantation genetic diagnosis (PNG) technique strategies and provide 
their necessary facilities. 
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Introduction1 
Thalassemia is the most common genetic disorder 
in humans which is an inherited globinopathy. It 
is estimated that about 4% to 7% of the world 
population i.e. 300 million are carriers of the gene. 
It is transmitted to the people due to mutation of 
genes that create α or β globulin chains. It is an 
autosomal recessive disorder leading to reduced 
production or non-production of β globin chains. 
Β-globin is identified by a structural gene that is 
located on the short arm of chromosome 11. More 
than 95% of all β-thalassemia mutations in the 
world are point mutation in β-type globin gene 
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and only a small percentage are gene-deleted. 
Nowadays, more than 200 mutations that affect  
β-globin gene have been identified that cause  
β-thalassemia phenotype. A small number of 
mutations, i.e. four mutations are responsible for 
the illness of 90% of patients.1-3 
If both β-gene chains are defective, the 
individual will be affected by major or severe 
thalassemia and anemia. β-thalassemia, which is 
the most common form of disease, has three 
types; mild (minor thalassemia or carrier); 
average (intermediate thalassemia); and severe 
(major Thalassemia).4 Because of anemia and 
increased erythropoietin, hematogenesis happens 
outside the bone marrow and liver and spleen 
may become enlarged. Extensive expansion of 
Health Care System 
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bone marrow impairs growth, change the face, 
and long bones and spinal column may suffer 
from pathological fractures. The disease may also 
cause hemolytic anemia, splenomegaly, leg 
ulcers, liver dysfunction, diabetes, zinc deficiency, 
metabolic disorders and heart failure.5,6 
In addition to the above mentioned physical 
problems, endocrine disorders are among the 
other complications of this disease. 
Hypogonadism is caused due to pituitary 
sensitivity to hypoxia; secondary amenorrhea, 
spermatogenous cell abnormalities, short stature, 
osteoporosis, osteopenia, hepatocellular 
carcinoma, and hepatitis C are the other 
complications 3,7,8. The disease can be diagnosed 
in childhood based on the symptoms of severe 
anemia, hypochrome, and microcytic 
hemoglobin. Disease can be treated either via 
frequent blood transfusions or using iron-
chelating drugs; both methods impose high costs 
on patients and society.3 
Thalasemia is an important health issue in 
high burden area because it could be prevented 
and its treatment has expensive cost.9,10 Based on 
thalassemia situation in Iran and without 
appropriate strategic for control of this diseases, it 
can have heavy burden in the country. Therefore, 
we have reviewed and discussed thalassemia 
program in Iran. The present study aimed to 
review the thalassemia program in Iran health 
system and existing studies about the thalassemia 
in Iran, the history of disease, and disease control 
strategies were reviewed. 
Materials and Methods 
This review was conducted according to hand 
and electronic resource. Hand research was done 
in books, guidelines and document that exist in 
thalassemia control program in Iranian Ministry 
of Health (MOH). We interviewed with experts in 
thalassemic office in several provinces for finding 
all documents about thalassemia program in Iran. 
These documents were reviewed for history, 
epidemiology and trend of the program by two 
researchers. Electronic search was done in the 
World Health Organization (WHO) internet site, 
MOH internet site, PubMed, Google Scholar, SID 
(scientific information database), Magiran and 
Iranmedex. We used thalassemia, epidemiology, 
program and Iran as keywords for searching. 
Abstract of papers were reviewed and full text of 
appropriate paper were studied accordingly. 
Results 
Distribution of thalassemia in the world 
The disease occurs worldwide and in all races. It 
is estimated approximately 1.5% of the world 
population are carriers of β-thalassemia and at 
least 60000 new cases are born annually.3 The 
disease has higher outbreak rate among the 
Mediterranean, i.e. Italy, Greece, Cyprus and 
Sicily Island, and also some parts of North and 
West Africa, the Middle East i.e. Iran, Turkey, 
Syria, and parts of east and south-east Asia, i.e. 
India and Pakistan; these countries and regions 
are commonly known as the thalassemia belt.3,9 
The disease is spread over south-west Europe to 
the Far East and it is seen in large areas of central 
Africa. Such a form of distribution is due to the 
spread of malaria which has been endemic to 
these regions for centuries; malaria parasite is 
unwilling to the red blood cells of thalassemia 
patients, therefore they are resistant against 
malaria.11 
Distribution of thalassemia in Iran 
In Iran, about 20,000 thalassemia patients have 
been registered until 2003. The disease has been 
spread all over the country, but it is more 
prevalent in the outlying parts of the Caspian Sea 
(Gillan, Mazandaran and Golestan), bordering 
parts of the Persian Gulf and Oman Sea (Bushehr, 
Hormozgan and Sistan-o-Baluchestan), and 
Khuzestan, Fars and South of Kerman provinces. 
In these areas, approximately 10% of the 
populations are β-thalassemia carriers while in 
other parts of the country, 3% to 8% are the 
carriers of the gene.11,12 
In Iran, there are about 2 to 3 million carriers.13 
The national program for control of thalassemia 
was started in Iran in 1996 and since then the 
emergence of new cases has reduced and number 
of thalassemia major patients was 13,000 to 14,000 
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people.14,15 It is estimated 1,000 thalassemia major 
patients are born in Iran annually. Recent studies 
have shown that β-thalassemia mutations in Iran 
are different and heterogenic and there are more 
than 60 different mutations in different 
geographical regions of the country.16-19 
Due to the high proportion of consanguineous 
marriages and its impact on gene pool, the rate of 
severe forms of the disease has been increased. 
The proportion of consanguineous marriages in 
Iran is 38%, from which 27.9% are the 
consanguineous marriages between cousins. 
Consequently, it is very important to screen and 
identify rare mutations in our population.12,20 
Because of the positive effects of thalassemia 
major prevention program, the number of 
newborns with β-thalassemia has been decreased. 
Since the initiation of the program, 2819 couples 
underwent prenatal diagnosis (PND) in genetic 
laboratory network of Iran. Age analysis of 
patients with severe symptoms of thalassemia has 
shown significant decrease of the number of 
thalassemia major cases.14 
Thalassemia control strategies in the world 
In areas in which thalassemia is common, 
different strategies for thalassemia control are 
recommended. These strategies include: 
• Identifying carriers: carriers can be detected 
since the birth. In some countries, in which 
thalassemia is very prevalent, thalassemia is 
detected at the time of marriage or prior to 
pregnancy. Sometimes this is done in school age or 
in a similar period. The simultaneous 
administration of such tests and actions to raise 
awareness can reduce the incidence of thalassemia. 
• Genetic counseling: before and after marriage 
and prior to pregnancy. 
•  Population screening: in specific populations 
and places where the disease is common. 
• Prenatal diagnosis: Experience shows that the 
use of aforementioned interventions may not 
result in successful prevention. Therefore, PND is 
considered as one of the most important 
thalassemia control strategies all over the 
world.2,21 
In addition to these strategies, there are some 
other important measures to be taken: 
• Public training  
• identifying target groups and covering 
them with important programs and measures to 
control the disease 
• improving the methods of detecting carriers 
• appropriate consultation 
• Providing molecular diagnosis 
• Diagnosis of mild disease phenotypes 
• Increasing access to PND 
• Facilitating the process of embryonic 
samples 
• Increasing access to DNA analysis 
• Promoting prevention programs, and 
• Allocation of resources for disease control.21 
A history of thalassemia control in Iran 
Thalassemia program pilot was initiated in Iran in 
1991 and pilot program was implemented in 
some districts. In that time, the main strategy of 
the program was to screen the couples prior to 
their marriage and to suggest separation of 
carriers and marrying a non-carrier. This strategy 
was carried out based on the following figure 
(Figure 1). In order to develop the program and 
since many carrier couples insisted on being 
married and were interested to have child, in 
1997, it was suggested to promote prenatal 
diagnosis.22. 
The second strategy was established in 2001. 
Based on this strategy, patients' families were 
identified and consultation services were 
provided for them. If they had not have healthy 
children, they were referred to prenatal diagnosis 
centers to have healthy children; consequently, 
genetic testing and prenatal care were developed 
in Iran. This has led to a dramatic reduction in 
new cases of β-thalassemia major. In addition, 
since all the partners were referring to 
laboratories, it became possible to investigate and 
control the incidence of the disease via a strong 
system. Figure 2 represents the strategy. 
The third strategy was started in provinces 
with high prevalence rates in 2005. Accordingly, 
the couples who had married prior to 1997 and  
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Figure 1. National algorithm of the steps of thalassemia tests (to detect β-thalassemia carrier couples) 
CBC: Complete blood count; MCV: Mean corpuscular volume; MCH: Mean corpuscular hemoglobin; HbA2: Hemoglobin, alpha 2. 
 
1. CBC for man 
MCV ≥ 80 and/or MCH ≥ 27 
No further 
action is 
needed 
(marriage 
permit) 
2. CBC for woman 
3. Measuring HbA2 in man and woman via 
column chromatography method 
HbA2 ≤ 3.5 in one or both of them 7 > HbA2 > 3.5 in both of them 
4. Treatment of iron deficiency anemia (as a 
diagnostic test) and re-evaluating the indexes 
and HbA  
Not-improving the 
indexes and HbA2 
> 3.5 in one or 
both of them 
Improving the 
indexes and HbA2 
≤ 3.5 in one or 
both of them 
5. Performing supplementary tests (globins chain and genetic tests) 
(Carrier 
partner) 
thalassemia 
specific 
counseling 
MCV < 80 and/or MCH < 27 
MCV ≥ 80 and/or MCH ≥ 27 MCV < 80 and/or MCH < 27 
Not-improving the 
indexes in one or both 
of them and HbA2 ≤ 3.5 
in one or both of them 
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Figure 2. Controlling β-thalassemia carrier couples 
Do they have a 
healthy child? 
First strategy Second and third strategies 
Are they willing 
to have more 
children? 
Suggesting safe 
contraceptive methods 
Performing the first step of prenatal diagnosis (PND) 
Performing the second step of prenatal diagnosis 
(PND) after pregnancy (10 weeks of pregnancy) 
Is the fetus a 
thalassemia major? 
Follow up for abortion 
(until 16 weeks of 
pregnancy) 
Pregnancy and childbirth care 
Continuing care based on guidelines 
(until the birth of healthy child) 
Training and referring for permanent 
contraceptive methods (vasectomy and 
tubectomy) 
Stopping 
follow-up 
Initiation of control procedure for β-thalassemia 
carrier couples (first, second, and third strategy) 
Yes 
No 
No 
Yes 
  
 
http://cdjournal.muk.ac.ir,    7 October 
  Chron Dis J, Vol. 1, No. 2, Autumn 2013     103 
Thalassemia control program in Iran  Moradi and Ghaderi 
had children/healthy children were tested to 
determine if they are carriers; the carriers were 
counseled to prevent the birth of children with 
thalassemia major (Figure 3). 
Genetic counseling and genetic diagnostic 
laboratory network was established in 2008 and 
was incorporated in the network system. The 
main tasks of the network were to counsel people 
and refer them for genetic testing and prenatal 
diagnosis of thalassemia. Each genetic counseling 
team was consisted of a physician and an expert. 
Teams were trained in real and virtual classes. 
The network was responsible for counseling 
couples who were both carriers. After counseling, 
if couples insisted on marriage, they would be 
referred to prenatal diagnosis centers and 
epidemiologic control departments in nearby 
health centers.11,23 
Preventing the birth of children with 
thalassemia major in Iran health system 
Currently, prevention of the birth of children 
with thalassemia major in Iran health system is 
performed through the following options: 
• First option: motivating carrier couples to 
cancel their marriage; 
Only couples who are both thalassemia 
carriers (minor) will have children with 
thalassemia major, so the easiest way to prevent 
the birth of children with thalassemia major is to 
motivate them not to marry each other. It was the 
basis of the first strategy of thalassemia major 
prevention at the beginning of the program. 
• Second option: Avoiding thalassemia couples 
from having children; 
The second option to prevent the birth of 
thalassemia major children included avoiding 
thalassemia couples from having children and 
motivating them to adopt a child if they were 
eager to have children. This was the basis for 
further development of thalassemia program in 
later phases. 
 
 
Figure 3. Detecting thalassemia major couples who married prior to 1997 
(for regions with high prevalence rates) 
CBC: Complete blood count; MCV: Mean corpuscular volume; MCH: Mean corpuscular hemoglobin; HbA2 
1. CBC for wife 
MCV ≥ 80 and/or MCH ≥ 27 
No further 
action is 
needed 
2. CBC for husband 
3. Referring to health centers that provide thalassemia counseling to continue 
the tests based on national algorithm  
MCV < 80 and/or MCH < 27 
MCV ≥ 80 and/or MCH ≥ 27 MCV < 80 and/or MCH < 27 
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• Third option: prenatal diagnosis (PND); 
PND and determining how genes are inherited 
from parents to embryos is the third option to 
prevent the birth of children with thalassemia 
major. The type of genes, their position, mutation 
type, and the inheritance status of the fetus from 
each couple should be determined. If defective 
genes are from both parents, the fetus will be a 
thalassemia major type and abortion will be the 
only alternative to prevent the birth of a 
thalassemia major child. This was the basis of the 
third strategy. Accordingly, in case of diagnosis of 
thalassemia major in the fetus, parents will be 
referred to coroners to receive permission for 
legal abortion. After authorization by 
gynecologists abortion is performed in a hospital. 
Legal limit for abortion is up to 16 weeks of 
pregnancy. Genetic tests and diagnostic 
procedures for prenatal diagnosis (PND) are as 
follows: 
First: In order to identify the gene and its 
mutation type, couple and sometimes some other 
family members are invited to do blood test. 
Second: After about 10 weeks of pregnancy, 
fetal tissue samples are prepared and the status of 
gene transfer is tested from parents to fetus.24 
The main objective is to assess the 
abnormalities at birth or chromosomal diseases 
(such as Down syndrome) or other genetic 
diseases. In many countries, if fetus is affected by 
diseases or if parents are not willing to have the 
baby, families are allowed to terminate pregnancy 
and do abortion. 
In cases where the family does not wish to do 
an abortion, prenatal diagnosis helps the 
treatment team and the family to become ready 
to deal effectively with birth of an infant who 
will have the disease. The other goal of prenatal 
diagnosis is to ensure parents who are concerned 
about their fetus. This is especially true in 
families who already had children with the 
disease. In Iran, in the case of early diagnosis of 
some diseases and following some legal 
observations, it is possible to do abortion. 
Prenatal diagnosis of thalassemia in Iran has 
become available since 1993. However, it was 
officially started in 1996, when abortion therapy  
was introduced.11,22 
Discussion 
Thalassemia program is appropriately structured 
and has been achieved successes especially in 
reduction in β-thalassemia major in Iran but in 
some areas thalassemia program has some defects 
and the program faced some cultural barrier.10,22,25 
The age of the patients has elevated because of 
good management of the diseases so we should 
note this situation in the surveillance program. 
Given the conditions in Iran, it may become 
necessary to use new methods of prenatal 
diagnosis. One of the other genetic approaches for 
prenatal diagnosis which is called PND is used to 
detect chromosomal abnormalities of the fetus 
before birth. However, when abnormalities in the 
fetus are detected, it is very difficult for the couple 
to make a decision for doing the abortion and it 
may lead to physical and psychological 
complications for them. Using [re-implantation 
genetic diagnosis (PGD) can avoid such problems. 
A new method has been developed to replace 
PND which can decrease its problems2. Pre-
implantation genetic diagnosis technique (PGD) 
is even one of the methods to determine of fetal 
sex as well by DNA analysis. This procedure can 
be done at approximately 15-18 weeks of 
gestation by amniocentesis, or at approximately 
10-12 weeks of gestation by chorionic villus 
sampling (CVS).26 The main purpose of using 
PGD is to prevent the transmission of genetic 
diseases from carrier parents to their children.  
Some PGD applications are as follows; for 
patients who underwent IVF (In vitro 
fertilization) or microinjection surgery more than 
3 times, but the surgeries did not result in 
pregnancy; when women are over 35 years of age; 
in case of structural anomalies such as trans-
location (displacement of chromosome fragments) 
found in couples' cerotype test; in case of multiple 
abortions when there is not any other reason for 
abortion; diagnosis of sex-linked diseases such as 
hemophilia which is particularly more prevalent 
in boys than girls; monogenic diseases such as 
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thalassemia, which may occur in the newborn. 
PGD can be used to separate a cell from a 
developing embryo and perform genetic 
experiments on it, and then the embryos that are 
free of genetic abnormalities are transferred to the 
womb, and expect a healthy baby without the 
need for abortion which was necessary in the 
older methods.27 This approach not only is more 
ethical but also will reduce psychological 
complications of couples. Furthermore, this 
method would be very helpful for people with 
religious attitudes who may not accept abortion.28 
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